Selected research
Market Structure
Global Rare Disease Pharmaceutical Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Rare Disease Pharmaceutical Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Rare Disease Pharmaceutical Service include Ultragenyx, Chiesi, Sciensus, Abbvie, Orpharma, Amgen, Recordati, Novartis and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Rare Disease Pharmaceutical Service market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rare Disease Pharmaceutical Service and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rare Disease Pharmaceutical Service revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Rare Disease Pharmaceutical Service market size, projected growth trends, production technologies, key applications, and end-use industries.
Rare Disease Pharmaceutical Service Segment by Company
Ultragenyx
Chiesi
Sciensus
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Shire
Merck
Pfizer
Biogen
Sanofi
AstraZeneca
Takeda
Rare Disease Pharmaceutical Service Segment by Type
Drug Discovery
Clinical Trials
Others
Rare Disease Pharmaceutical Service Segment by Application
Congenital and Genetic Diseases
Tumors and Cancer
Endocrine Diseases
Others
Rare Disease Pharmaceutical Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Pharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Pharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Pharmaceutical Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Rare Disease Pharmaceutical Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rare Disease Pharmaceutical Service industry.
Chapter 3: Detailed analysis of Rare Disease Pharmaceutical Service companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Pharmaceutical Servicerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032
Table 2. Key Players of Drug Discovery
Table 3. Key Players of Clinical Trials
Table 4. Key Players of Others
Table 4. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032
Table 5. Key Players of Congenital and Genetic Diseases
Table 6. Key Players of Tumors and Cancer
Table 7. Key Players of Endocrine Diseases
Table 8. Key Players of Others
Table 9. Global Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 10. Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2026) & (US$ Million)
Table 11. Global Rare Disease Pharmaceutical Service Market Share by Region (2021-2026)
Table 12. Global Rare Disease Pharmaceutical Service Market Size by Region (2027-2032) & (US$ Million)
Table 13. Global Rare Disease Pharmaceutical Service Market Share by Region (2027-2032)
Table 14. Rare Disease Pharmaceutical Service Industry Trends
Table 15. Rare Disease Pharmaceutical Service Industry Drivers
Table 16. Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
Table 17. Rare Disease Pharmaceutical Service Industry Restraints
Table 18. Global Rare Disease Pharmaceutical Service Revenue by Company (US$ Million) & (2021-2026)
Table 19. Global Rare Disease Pharmaceutical Service Revenue Market Share by Company (2021-2026)
Table 20. Global Rare Disease Pharmaceutical Service Players Revenue Ranking, 2024 VS 2025 VS 2026
Table 21. Global Rare Disease Pharmaceutical Service Key Company Head Office and Area Served
Table 22. Global Rare Disease Pharmaceutical Service Company, Product Type & Application
Table 23. Global Rare Disease Pharmaceutical Service Company Establishment Date
Table 24. Global Company Market Concentration Ratio (CR5 and HHI)
Table 25. Global Rare Disease Pharmaceutical Service by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 26. Global Rare Disease Pharmaceutical Service Market Size by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 28. Global Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 29. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2021-2026)
Table 30. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2027-2032)
Table 31. Global Rare Disease Pharmaceutical Service Market Size by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 33. Global Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 34. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021-2026)
Table 35. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2027-2032)
Table 36. Ultragenyx Company Information
Table 37. Ultragenyx Business Overview
Table 38. Ultragenyx Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 39. Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
Table 40. Ultragenyx Recent Development
Table 41. Chiesi Company Information
Table 42. Chiesi Business Overview
Table 43. Chiesi Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 44. Chiesi Rare Disease Pharmaceutical Service Product Portfolio
Table 45. Chiesi Recent Development
Table 46. Sciensus Company Information
Table 47. Sciensus Business Overview
Table 48. Sciensus Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 49. Sciensus Rare Disease Pharmaceutical Service Product Portfolio
Table 50. Sciensus Recent Development
Table 51. Abbvie Company Information
Table 52. Abbvie Business Overview
Table 53. Abbvie Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 54. Abbvie Rare Disease Pharmaceutical Service Product Portfolio
Table 55. Abbvie Recent Development
Table 56. Orpharma Company Information
Table 57. Orpharma Business Overview
Table 58. Orpharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 59. Orpharma Rare Disease Pharmaceutical Service Product Portfolio
Table 60. Orpharma Recent Development
Table 61. Amgen Company Information
Table 62. Amgen Business Overview
Table 63. Amgen Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 64. Amgen Rare Disease Pharmaceutical Service Product Portfolio
Table 65. Amgen Recent Development
Table 66. Recordati Company Information
Table 67. Recordati Business Overview
Table 68. Recordati Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 69. Recordati Rare Disease Pharmaceutical Service Product Portfolio
Table 70. Recordati Recent Development
Table 71. Novartis Company Information
Table 72. Novartis Business Overview
Table 73. Novartis Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 74. Novartis Rare Disease Pharmaceutical Service Product Portfolio
Table 75. Novartis Recent Development
Table 76. Celgene Company Information
Table 77. Celgene Business Overview
Table 78. Celgene Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 79. Celgene Rare Disease Pharmaceutical Service Product Portfolio
Table 80. Celgene Recent Development
Table 81. Amryt Pharma Company Information
Table 82. Amryt Pharma Business Overview
Table 83. Amryt Pharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 84. Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
Table 85. Amryt Pharma Recent Development
Table 86. Johnson & Johnson Company Information
Table 87. Johnson & Johnson Business Overview
Table 88. Johnson & Johnson Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 89. Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
Table 90. Johnson & Johnson Recent Development
Table 91. GSK Company Information
Table 92. GSK Business Overview
Table 93. GSK Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 94. GSK Rare Disease Pharmaceutical Service Product Portfolio
Table 95. GSK Recent Development
Table 96. Shire Company Information
Table 97. Shire Business Overview
Table 98. Shire Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 99. Shire Rare Disease Pharmaceutical Service Product Portfolio
Table 100. Shire Recent Development
Table 101. Merck Company Information
Table 102. Merck Business Overview
Table 103. Merck Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 104. Merck Rare Disease Pharmaceutical Service Product Portfolio
Table 105. Merck Recent Development
Table 106. Pfizer Company Information
Table 107. Pfizer Business Overview
Table 108. Pfizer Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 109. Pfizer Rare Disease Pharmaceutical Service Product Portfolio
Table 110. Pfizer Recent Development
Table 111. Biogen Company Information
Table 112. Biogen Business Overview
Table 113. Biogen Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 114. Biogen Rare Disease Pharmaceutical Service Product Portfolio
Table 115. Biogen Recent Development
Table 116. Sanofi Company Information
Table 117. Sanofi Business Overview
Table 118. Sanofi Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 119. Sanofi Rare Disease Pharmaceutical Service Product Portfolio
Table 120. Sanofi Recent Development
Table 121. AstraZeneca Company Information
Table 122. AstraZeneca Business Overview
Table 123. AstraZeneca Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 124. AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
Table 125. AstraZeneca Recent Development
Table 126. Takeda Company Information
Table 127. Takeda Business Overview
Table 128. Takeda Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 129. Takeda Rare Disease Pharmaceutical Service Product Portfolio
Table 130. Takeda Recent Development
Table 131. North America Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 132. North America Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 133. North America Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 134. North America Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 135. North America Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 136. North America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
Table 137. North America Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
Table 138. Europe Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 139. Europe Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 140. Europe Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 141. Europe Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 142. Europe Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 143. Europe Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
Table 144. Europe Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
Table 145. China Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 146. China Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 147. China Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 148. China Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 149. Asia Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 150. Asia Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 151. Asia Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 152. Asia Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 153. Asia Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 154. Asia Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
Table 155. Asia Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
Table 156. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 157. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Type (2027-2032) & (US$ Million)
Table 158. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 159. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Application (2027-2032) & (US$ Million)
Table 160. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 161. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
Table 162. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
Table 163. Research Programs/Design for This Report
Table 164. Authors List of This Report
Table 165. Secondary Sources
Table 166. Primary Sources
List of Figures
Figure 1. Rare Disease Pharmaceutical Service Product Image
Figure 2. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million)
Figure 3. Global Rare Disease Pharmaceutical Service Market Share by Type: 2025 VS 2032
Figure 4. Drug Discovery Image
Figure 5. Clinical Trials Image
Figure 6. Others Image
Figure 7. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million)
Figure 8. Global Rare Disease Pharmaceutical Service Market Share by Application: 2025 VS 2032
Figure 9. Congenital and Genetic Diseases Image
Figure 10. Tumors and Cancer Image
Figure 11. Endocrine Diseases Image
Figure 12. Others Image
Figure 13. Global Rare Disease Pharmaceutical Service Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 14. Global Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 15. Global Rare Disease Pharmaceutical Service Market Share by Region: 2025 VS 2032
Figure 16. Years Considered
Figure 17. Global Rare Disease Pharmaceutical Service Market Share by Players in 2025
Figure 18. Global Top 5 and 10 Rare Disease Pharmaceutical Service Players Market Share by Revenue in 2025
Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Rare Disease Pharmaceutical Service Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 21. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2021-2032)
Figure 22. Global Rare Disease Pharmaceutical Service Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 23. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021-2032)
Figure 24. North America Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 25. North America Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
Figure 26. North America Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
Figure 27. North America Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 28. United States Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 29. Canada Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 30. Mexico Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 31. Europe Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 32. Europe Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
Figure 33. Europe Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
Figure 34. Europe Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 35. Germany Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 36. France Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 37. U.K. Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 38. Italy Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 39. Russia Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 40. Nordic Countries Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 41. China Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 42. China Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
Figure 43. China Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
Figure 44. Asia Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 45. Asia Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
Figure 46. Asia Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
Figure 47. Asia Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 48. Japan Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 49. South Korea Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 50. Taiwan Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 52. India Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 53. Australia Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 54. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 55. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
Figure 56. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
Figure 57. South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 58. Brazil Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 59. South Africa Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 60. Saudi Arabia Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 61. Turkey Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 62. Argentina Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 63. UAE Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 64. Egypt Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 65. Chile Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 66. Research Process
Figure 67. Key Executives Interviewed
Scope & coverage.
Types
- Drug Discovery
- Clinical Trials
- Others
Applications
- Congenital and Genetic Diseases
- Tumors and Cancer
- Endocrine Diseases
- Others
Companies covered
- Ultragenyx
- Chiesi
- Sciensus
- Abbvie
- Orpharma
- Amgen
- Recordati
- Novartis
- Celgene
- Amryt Pharma
- Johnson & Johnson
- GSK
- Shire
- Merck
- Pfizer
- Biogen
- Sanofi
- AstraZeneca
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Drug Discovery
- 1.2.3 Clinical Trials
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Congenital and Genetic Diseases
- 1.3.3 Tumors and Cancer
- 1.3.4 Endocrine Diseases
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Rare Disease Pharmaceutical Service Growth Trends by Region
- 1.5.1 Global Rare Disease Pharmaceutical Service Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Rare Disease Pharmaceutical Service Market Size by Region (2021-2026)
- 1.5.3 Rare Disease Pharmaceutical Service Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Rare Disease Pharmaceutical Service Market Dynamics
- 2.1 Rare Disease Pharmaceutical Service Industry Trends
- 2.2 Rare Disease Pharmaceutical Service Industry Drivers
- 2.3 Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
- 2.4 Rare Disease Pharmaceutical Service Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Rare Disease Pharmaceutical Service Revenue by Company (2021-2026)
- 3.2 Global Rare Disease Pharmaceutical Service Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Rare Disease Pharmaceutical Service Key Company Head office and Area Served
- 3.4 Global Rare Disease Pharmaceutical Service Company, Product Type & Application
- 3.5 Global Rare Disease Pharmaceutical Service Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Rare Disease Pharmaceutical Service Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Rare Disease Pharmaceutical Service Players Market Share by Revenue in 2025
- 3.6.3 2025 Rare Disease Pharmaceutical Service Tier 1, Tier 2, and Tier 3
4 Rare Disease Pharmaceutical Service Market by Type
- 4.1 Global Rare Disease Pharmaceutical Service Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Rare Disease Pharmaceutical Service Market Size by Type (2021-2032)
- 4.3 Global Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
5 Rare Disease Pharmaceutical Service Market by Application
- 5.1 Global Rare Disease Pharmaceutical Service Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Rare Disease Pharmaceutical Service Market Size by Application (2021-2032)
- 5.3 Global Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Ultragenyx
- 6.1.1 Ultragenyx Company Information
- 6.1.2 Ultragenyx Business Overview
- 6.1.3 Ultragenyx Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
- 6.1.5 Ultragenyx Recent Developments
- 6.2 Chiesi
- 6.2.1 Chiesi Company Information
- 6.2.2 Chiesi Business Overview
- 6.2.3 Chiesi Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Chiesi Rare Disease Pharmaceutical Service Product Portfolio
- 6.2.5 Chiesi Recent Developments
- 6.3 Sciensus
- 6.3.1 Sciensus Company Information
- 6.3.2 Sciensus Business Overview
- 6.3.3 Sciensus Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sciensus Rare Disease Pharmaceutical Service Product Portfolio
- 6.3.5 Sciensus Recent Developments
- 6.4 Abbvie
- 6.4.1 Abbvie Company Information
- 6.4.2 Abbvie Business Overview
- 6.4.3 Abbvie Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Abbvie Rare Disease Pharmaceutical Service Product Portfolio
- 6.4.5 Abbvie Recent Developments
- 6.5 Orpharma
- 6.5.1 Orpharma Company Information
- 6.5.2 Orpharma Business Overview
- 6.5.3 Orpharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Orpharma Rare Disease Pharmaceutical Service Product Portfolio
- 6.5.5 Orpharma Recent Developments
- 6.6 Amgen
- 6.6.1 Amgen Company Information
- 6.6.2 Amgen Business Overview
- 6.6.3 Amgen Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Amgen Rare Disease Pharmaceutical Service Product Portfolio
- 6.6.5 Amgen Recent Developments
- 6.7 Recordati
- 6.7.1 Recordati Company Information
- 6.7.2 Recordati Business Overview
- 6.7.3 Recordati Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Recordati Rare Disease Pharmaceutical Service Product Portfolio
- 6.7.5 Recordati Recent Developments
- 6.8 Novartis
- 6.8.1 Novartis Company Information
- 6.8.2 Novartis Business Overview
- 6.8.3 Novartis Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Novartis Rare Disease Pharmaceutical Service Product Portfolio
- 6.8.5 Novartis Recent Developments
- 6.9 Celgene
- 6.9.1 Celgene Company Information
- 6.9.2 Celgene Business Overview
- 6.9.3 Celgene Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Celgene Rare Disease Pharmaceutical Service Product Portfolio
- 6.9.5 Celgene Recent Developments
- 6.10 Amryt Pharma
- 6.10.1 Amryt Pharma Company Information
- 6.10.2 Amryt Pharma Business Overview
- 6.10.3 Amryt Pharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
- 6.10.5 Amryt Pharma Recent Developments
- 6.11 Johnson & Johnson
- 6.11.1 Johnson & Johnson Company Information
- 6.11.2 Johnson & Johnson Business Overview
- 6.11.3 Johnson & Johnson Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
- 6.11.5 Johnson & Johnson Recent Developments
- 6.12 GSK
- 6.12.1 GSK Company Information
- 6.12.2 GSK Business Overview
- 6.12.3 GSK Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 GSK Rare Disease Pharmaceutical Service Product Portfolio
- 6.12.5 GSK Recent Developments
- 6.13 Shire
- 6.13.1 Shire Company Information
- 6.13.2 Shire Business Overview
- 6.13.3 Shire Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Shire Rare Disease Pharmaceutical Service Product Portfolio
- 6.13.5 Shire Recent Developments
- 6.14 Merck
- 6.14.1 Merck Company Information
- 6.14.2 Merck Business Overview
- 6.14.3 Merck Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Merck Rare Disease Pharmaceutical Service Product Portfolio
- 6.14.5 Merck Recent Developments
- 6.15 Pfizer
- 6.15.1 Pfizer Company Information
- 6.15.2 Pfizer Business Overview
- 6.15.3 Pfizer Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Pfizer Rare Disease Pharmaceutical Service Product Portfolio
- 6.15.5 Pfizer Recent Developments
- 6.16 Biogen
- 6.16.1 Biogen Company Information
- 6.16.2 Biogen Business Overview
- 6.16.3 Biogen Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Biogen Rare Disease Pharmaceutical Service Product Portfolio
- 6.16.5 Biogen Recent Developments
- 6.17 Sanofi
- 6.17.1 Sanofi Company Information
- 6.17.2 Sanofi Business Overview
- 6.17.3 Sanofi Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Sanofi Rare Disease Pharmaceutical Service Product Portfolio
- 6.17.5 Sanofi Recent Developments
- 6.18 AstraZeneca
- 6.18.1 AstraZeneca Company Information
- 6.18.2 AstraZeneca Business Overview
- 6.18.3 AstraZeneca Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
- 6.18.5 AstraZeneca Recent Developments
- 6.19 Takeda
- 6.19.1 Takeda Company Information
- 6.19.2 Takeda Business Overview
- 6.19.3 Takeda Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 Takeda Rare Disease Pharmaceutical Service Product Portfolio
- 6.19.5 Takeda Recent Developments
7 North America
- 7.1 North America Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 7.2 North America Rare Disease Pharmaceutical Service Market Size by Type
- 7.2.1 North America Rare Disease Pharmaceutical Service Market Size by Type (2021-2026)
- 7.2.2 North America Rare Disease Pharmaceutical Service Market Size by Type (2027-2032)
- 7.2.3 North America Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
- 7.3 North America Rare Disease Pharmaceutical Service Market Size by Application
- 7.3.1 North America Rare Disease Pharmaceutical Service Market Size by Application (2021-2026)
- 7.3.2 North America Rare Disease Pharmaceutical Service Market Size by Application (2027-2032)
- 7.3.3 North America Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
- 7.4 North America Rare Disease Pharmaceutical Service Market Size by Country
- 7.4.1 North America Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 7.4.3 North America Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 7.4.4 North America Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 8.2 Europe Rare Disease Pharmaceutical Service Market Size by Type
- 8.2.1 Europe Rare Disease Pharmaceutical Service Market Size by Type (2021-2026)
- 8.2.2 Europe Rare Disease Pharmaceutical Service Market Size by Type (2027-2032)
- 8.2.3 Europe Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
- 8.3 Europe Rare Disease Pharmaceutical Service Market Size by Application
- 8.3.1 Europe Rare Disease Pharmaceutical Service Market Size by Application (2021-2026)
- 8.3.2 Europe Rare Disease Pharmaceutical Service Market Size by Application (2027-2032)
- 8.3.3 Europe Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
- 8.4 Europe Rare Disease Pharmaceutical Service Market Size by Country
- 8.4.1 Europe Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 8.4.3 Europe Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 8.4.4 Europe Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 9.2 China Rare Disease Pharmaceutical Service Market Size by Type
- 9.2.1 China Rare Disease Pharmaceutical Service Market Size by Type (2021-2026)
- 9.2.2 China Rare Disease Pharmaceutical Service Market Size by Type (2027-2032)
- 9.2.3 China Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
- 9.3 China Rare Disease Pharmaceutical Service Market Size by Application
- 9.3.1 China Rare Disease Pharmaceutical Service Market Size by Application (2021-2026)
- 9.3.2 China Rare Disease Pharmaceutical Service Market Size by Application (2027-2032)
- 9.3.3 China Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 10.2 Asia Rare Disease Pharmaceutical Service Market Size by Type
- 10.2.1 Asia Rare Disease Pharmaceutical Service Market Size by Type (2021-2026)
- 10.2.2 Asia Rare Disease Pharmaceutical Service Market Size by Type (2027-2032)
- 10.2.3 Asia Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
- 10.3 Asia Rare Disease Pharmaceutical Service Market Size by Application
- 10.3.1 Asia Rare Disease Pharmaceutical Service Market Size by Application (2021-2026)
- 10.3.2 Asia Rare Disease Pharmaceutical Service Market Size by Application (2027-2032)
- 10.3.3 Asia Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
- 10.4 Asia Rare Disease Pharmaceutical Service Market Size by Country
- 10.4.1 Asia Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 10.4.3 Asia Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 10.4.4 Asia Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Type
- 11.2.1 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Application
- 11.3.1 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country
- 11.4.1 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst